ERBB2 and cancer: An ER+ subgroup with specific alterations was found to exhibit a high mortality risk, whereas ERBB2-amplified cancers including both HER2-enriched (ER−) cases and other luminal (ER+) cases formed a cluster that improved the definition of the ERBB2 intrinsic subtype by grouping additional patients expected to benefit from targeted therapy.